DCGN, AFFX to develop DNA tests

deCode will combine its population-based approach to pharmacogenomics with Affymetrix's GeneChip technology to develop DNA-based tests to predict patient responsiveness to treatments. Initially the deal will focus on gene expression analysis to understand conditions such as high cholesterol, depression, asthma, hypertension, breast cancer, schizophrenia and migraine. DCGN subsidiary Encode will undertake the required clinical work. DCGN and AFFX will share revenues from the sale of the tests. ...